MET and lung carcinoma: The amplification of cMet is a major factor of acquired resistance in lung cancer and the combination of Gefitinib and cMet antibody can significantly enhance the growth inhibition in cMet over-expressing cell lines (Bean et al., 2007; Zucali et al., 2008).